Medscape

Medscape is a reputable source of medical news and information for healthcare professionals. The site provides up-to-date information on the latest research, drugs, treatments, and medical conferences. While there are occasional contradictions, conflicts of interest, and instances of deceptive practices, these are generally rare and not a consistent issue. The site has a slight bias towards providing accurate and up-to-date information for its audience.

82%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

85%

Examples:

  • The site has a slight bias towards providing up-to-date and accurate information for healthcare professionals.

Conflicts of Interest

85%

Examples:

  • The site occasionally has conflicts of interest, such as reporting on a new drug or treatment that a writer or their institution may have a financial stake in. However, this is rare and not a consistent issue.

Contradictions

90%

Examples:

  • There are occasional contradictions found in the articles, but they are usually related to recent research or new developments in medicine.

Deceptions

75%

Examples:

  • The site occasionally uses misleading headlines or presents information in a way that can be confusing or deceptive, such as implying a causal relationship between vaccines and long COVID without providing strong evidence to support this claim.

Recent Articles

  • Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

    Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

    Broke On: Wednesday, 03 July 2024 A recent study published in JAMA Ophthalmology found that patients taking semaglutide, a medication for diabetes and obesity, had a significantly higher risk of developing Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which can cause vision loss. The incidence rate was 4.28 times higher in type 2 diabetes patients and 7.64 times higher in overweight or obese patients taking semaglutide compared to non-GLP-1 RA medications.
  • 1 in 5 Americans Miss Out on Lung Cancer Screenings: Alarming Statistics and Solutions

    1 in 5 Americans Miss Out on Lung Cancer Screenings: Alarming Statistics and Solutions

    Broke On: Monday, 01 July 2024 Recent studies reveal that only 1 in 5 eligible Americans receive annual lung cancer screenings, despite recommendations for high-risk individuals. Compliance rates vary significantly by state and age, with older adults showing higher adherence. Medicaid expansion appears to correlate with higher screening rates. Innovative approaches like natural language processing and patient navigators can help increase awareness and accessibility to lung cancer screenings.
  • New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    Broke On: Tuesday, 25 June 2024 New clinical trials show that Eli Lilly's tirzepatide injection, used for diabetes and weight loss, significantly reduces sleep disruptions in obstructive sleep apnea patients. Up to 50% of trial participants no longer needed CPAP devices and experienced lower C-reactive protein levels, systolic blood pressure, and an average weight loss of 18%-20%. The SURMOUNT-OSA studies mark a major advancement in OSA treatment.
  • Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

    Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

    Broke On: Sunday, 23 June 2024 Semaglutide, a weight-loss drug marketed as Wegovy or Ozempic, significantly reduces major adverse cardiovascular events (MACEs) by 20% for individuals with overweight or obesity and cardiovascular disease. The SELECT trial revealed that semaglutide users sustained weight loss for up to four years, dropped an average of 10% of their body weight, and showed improvements in heart health regardless of the amount lost. Semaglutide's benefits held up for all subgroups and normal A1c levels at baseline.
  • Urgent Action Needed: Experts Warn of Potential Pandemic from Bird Flu Virus Spreading Among Dairy Farms

    Urgent Action Needed: Experts Warn of Potential Pandemic from Bird Flu Virus Spreading Among Dairy Farms

    Broke On: Monday, 17 June 2024 Amidst growing concerns, the bird flu virus (H5N1) is spreading among dairy farms in the US, potentially mutating to infect people more easily and cause a new pandemic. Former CDC director Robert Redfield predicts a mortality rate between 25%-50%, warning that human cases may be overlooked due to limited testing. Authorities recommend preventative measures like hand washing and avoiding animal contact, while urging action to prevent potential dangers.
  • New Blood Test Predicts Parkinson's Disease Seven Years Before Symptoms Appear: A Game Changer in Early Detection

    New Blood Test Predicts Parkinson's Disease Seven Years Before Symptoms Appear: A Game Changer in Early Detection

    Broke On: Wednesday, 19 June 2024 A new blood test using artificial intelligence identifies eight biomarkers to predict Parkinson's disease up to seven years before symptoms appear, potentially revolutionizing diagnosis and treatment of this neurodegenerative disorder.
  • New Male Birth Control Gel Shows Promise in Clinical Trials: Effectively Reduces Sperm Production in 8 Weeks

    New Male Birth Control Gel Shows Promise in Clinical Trials: Effectively Reduces Sperm Production in 8 Weeks

    Broke On: Wednesday, 05 June 2024 A new hormonal gel for male birth control, which men apply on their shoulders, effectively reduces sperm production within eight weeks according to clinical trials. The rapid suppression of sperm makes it a significant advancement in male contraceptive options and an essential step towards gender equality.
  • New 30-Year Study: Limiting Consumption of Processed Meats, Sugary Foods and Drinks Linked to Lower Risk of Death

    New 30-Year Study: Limiting Consumption of Processed Meats, Sugary Foods and Drinks Linked to Lower Risk of Death

    Broke On: Wednesday, 08 May 2024 A 30-year study of over 100,000 adults reveals that high consumption of ultra-processed foods like processed meats, sugary drinks, and dairy-based desserts increases mortality risk by 4%, with a higher risk (9%) for neurodegenerative deaths. A healthy diet rich in whole foods is key to reducing death risk. Previous research links ultra-processed diets to 32 damaging health outcomes, including cancer, heart and lung conditions, obesity, type 2 diabetes, and early death.
  • New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

    New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

    Broke On: Tuesday, 09 April 2024 A new study published in The Lancet found that stopping aspirin one month after percutaneous coronary intervention (PCI) for an acute coronary syndrome significantly reduces bleeding complications in heart attack patients. This is the first time a placebo-controlled trial has confirmed this finding, and it was presented at the American College of Cardiology 2024 Scientific Sessions on Sunday, April 7th.
  • Hair-Straightening Products with Glyoxylic Acid Linked to Acute Kidney Failure Risk

    Hair-Straightening Products with Glyoxylic Acid Linked to Acute Kidney Failure Risk

    Broke On: Thursday, 28 March 2024 Hair-straightening products containing glyoxylic acid have been linked to acute kidney failure risk. The use of these products has resulted in the accumulation of calcium oxalate crystals in the kidneys, which can lead to severe renal damage. Several cases have been reported where women experienced repeated episodes of acute kidney injury after receiving hair-straightening treatments at a salon using glyoxylic acid creams.